Login to Your Account



Early Data Show Promise with Adaptimmune's T-Cell Platform

By Nuala Moran
Staff Writer

Tuesday, November 20, 2012
Adaptimmune Ltd. has published the first clinical data on its genetically modified T-cell technology, saying infusion of the engineered cells is safe, well tolerated and leads to a high response rate in a high-risk multiple myeloma population.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription